ArticleInteractive journal of medical research2021
Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study.
Article in Interactive journal of medical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Evaluation of ornithogalum sigmoideum extract-induced cytotoxicity and expression of xenobiotic metabolism-related genes in HT29 cells.Molecular biology reports · 2026Article
- Expression and Clinical Significance of Cytochrome 1B1 in Bone Sarcomas.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploration and validation of the prognostic value of mitophagy and mitochondrial dynamics-related genes in cervical cancer.Scientific reports · 2025Article
- The Cytochrome CYP4 in Breast and Other Cancers.Biology · 2025Review
- ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical Adenocarcinoma: Bioinformatic Analysis and Experimental Verification.Current gene therapy · 2024Article
- The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications.Cell death & disease · 2023Review
- Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention.Biomedicines · 2023Review
- Design of Cytochrome P450 1B1 InhibitorsJournal of medicinal chemistry · 2023Article
- Phytochemical Analysis and Profiling of Antitumor Compounds of Leaves and Stems ofMolecules (Basel, Switzerland) · 2023Article
- Glypican-3 Differentiates Intraductal Carcinoma and Paget's Disease from Other Types of Breast Cancer.Medicina (Kaunas, Lithuania) · 2022Article
- Evidence-based capacity of natural cytochrome enzyme inhibitors to increase the effectivity of antineoplastic drugs.Discover oncology · 2022Review
- piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner.Journal of translational medicine · 2022Article
- Cytochrome 4Z1 Expression is Associated with Poor Prognosis in Colon Cancer Patients.OncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent standard treatments for patients with recurrent cervical cancer are not very effective and are associated with severe toxicity. Recently, the rational approach for the discovery of new therapies for cervical cancer is based on the alterations in the molecular biology of cancer cells. One of the emerging molecular changes in cancer cells is the aberrant expression of cytochrome P450 1B1 (CYP1B1). This unique enzyme has been reported to be selectively overexpressed in several cancers.
objectiveThe aim of this study was to examine CYP1B1 expression in cervical cancers and to assess the enzyme's relationship with several clinicopathological features.
methodsImmunohistochemistry was performed to examine CYP1B1 expression in 100 patient samples with cervical cancer and 10 patient samples with normal healthy cervical tissues.
resultsCYP1B1 was expressed in the majority of the cervical cancer samples (91/100, 91.0%) but not in normal healthy cervical samples. The difference in the expression of CYP1B1 between healthy and tumorous cervical tissues was significant (P=.01). Moreover, the frequency of CYP1B1 expression was found to be significantly higher in patients with advanced grades of the disease (P=.03) and in patients having metastasis to the lymph nodes (P=.01). Surprisingly, there was a significantly higher expression of CYP1B1 in patients with a high prevalence of human papilloma virus 16/18 (P=.04).
conclusionsThe differential profile of CYP1B1 expression between cervical cancer tissues and normal cervical tissues suggests that CYP1B1 may be used as a target for future therapeutic exploitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.